Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis

Zhou,Jin‑An; Jiang,Mingshan; Yang,Xinguang; Liu,Yuanli; Guo,Junyu; Zheng,Jiadong; Qu,Yilin; Song,Yu; Li,Rongyan; Qin,Xiaofa; Wang,Xiuhong

doi:10.3892/mmr.2017.6825

Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis

Authors:
- Jin‑An Zhou
- Mingshan Jiang
- Xinguang Yang
- Yuanli Liu
- Junyu Guo
- Jiadong Zheng
- Yilin Qu
- Yu Song
- Rongyan Li
- Xiaofa Qin
- Xiuhong Wang
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Heilongjiang Provincial Science and Technology Innovation Team in Higher Education Institutes for Infection and Immunity, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Biochemistry and Molecular Biology, Daqing Branch of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China, GI Biopharma Inc., Westfield, NJ 07090, USA
Published online on: June 21, 2017 https://doi.org/10.3892/mmr.2017.6825
Pages: 1779-1784
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The authors previously demonstrated that unconjugated bilirubin (UCB) may inhibit the activities of various digestive proteases, including trypsin and chymotrypsin. The digestive proteases in the lower gut are important in the pathogenesis of inflammatory bowel diseases. The effects of UCB on the inflammation and levels of digestive proteases in feces of rats with colitis have not yet been revealed. The present study investigated the effect of UCB on the inflammatory status and levels of trypsin and chymotrypsin in the feces of rats with trinitrobenzenesulfonic acid (TNBS)‑induced colitis. The data indicated that treatment with TNBS resulted in a marked reduction in weight gain, which was significantly alleviated in UCB‑treated rats. Furthermore, UCB treatment alleviated the inflammation induced by TNBS, detected via macroscopic damage and microscopic inflammation scores, and pro‑inflammatory markers including myeloperoxidase (MPO), tumor necrosis factor (TNF)‑α and interleukin (IL)‑1β. Furthermore, rats with colitis demonstrated significant increases in fecal trypsin and chymotrypsin levels, whereas UCB treatment significantly alleviated these increases. A significant positive correlation was additionally revealed among the pro‑inflammatory markers (MPO, TNF‑α and IL‑1β) and fecal digestive proteases (trypsin and chymotrypsin) in colitis. The results of the present study demonstrated that UCB ameliorated the inflammation and digestive protease increase in TNBS-induced colitis.

View Figures

View References

1	Bouma G and Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 3:521–533. 2003. View Article : Google Scholar : PubMed/NCBI
2	Mokry M, Middendorp S, Wiegerinck CL, Witte M, Teunissen H, Meddens CA, Cuppen E, Clevers H and Nieuwenhuis EE: Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology. 146:1040–1047. 2014. View Article : Google Scholar : PubMed/NCBI
3	Cosnes J, Gower-Rousseau C, Seksik P and Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140:1785–1794. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kirsner JB: The historical basis of the idiopathic inflammatory bowel diseases. Inflammatory Bowel Dis. 1:2–26. 1995. View Article : Google Scholar
5	Pithadia AB and Jain S: Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 63:629–642. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rietdijk ST and D'Haens GR: Recent developments in the treatment of inflammatory bowel disease. J Dig Dis. 14:282–287. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sohrabpour AA, Malekzadeh R and Keshavarzian A: Current therapeutic approaches in inflammatory bowel disease. Curr Pharm Des. 16:3668–3683. 2010. View Article : Google Scholar : PubMed/NCBI
8	van de Merwe JP and Mol GJ: Levels of Trypsin and alpha-chymotrypsin in feces from patients with Crohn's disease. Digestion. 24:1–4. 1982. View Article : Google Scholar : PubMed/NCBI
9	Maeda S, Ohno K, Uchida K, Igarashi H, Goto-Koshino Y, Fujino Y and Tsujimoto H: Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression. J Vet Med Sci. 76:1119–1127. 2014. View Article : Google Scholar : PubMed/NCBI
10	Midtvedt T, Zabarovsky E, Norin E, Bark J, Gizatullin R, Kashuba V, Ljungqvist O, Zabarovska V, Möllby R and Ernberg I: Increase of faecal tryptic activity relates to changes in the intestinal microbiome: Analysis of Crohn's disease with a multidisciplinary platform. PLoS One. 8:e660742013. View Article : Google Scholar : PubMed/NCBI
11	Safavi F and Rostami A: Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp Mol Pathol. 93:428–433. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, et al: Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 13:975–980. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gran B, Tabibzadeh N, Martin A, Ventura ES, Ware JH, Zhang GX, Parr JL, Kennedy AR and Rostami AM: The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: A potential oral therapy for multiple sclerosis. Mult Scler. 12:688–697. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR and Ware JH: Bowman-Birk inhibitor concentrate: A novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci. 53:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ware JH, Wan XS, Newberne P and Kennedy AR: Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig Dis Sci. 44:986–990. 1999. View Article : Google Scholar : PubMed/NCBI
16	Qin XF: Impaired inactivation of digestive proteases by deconjugated bilirubin: The possible mechanism for inflammatory bowel disease. Med Hypotheses. 59:159–163. 2002. View Article : Google Scholar : PubMed/NCBI
17	Bermúdez-Humarán LG, Motta JP, Aubry C, Kharrat P, Rous-Martin L, Sallenave JM, Deraison C, Vergnolle N and Langella P: Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb Cell Fact. 14:262015. View Article : Google Scholar : PubMed/NCBI
18	Stocker R, Yamamoto Y, McDonagh AF, Glazer AN and Ames BN: Bilirubin is an antioxidant of possible physiological importance. Science. 235:1043–1046. 1987. View Article : Google Scholar : PubMed/NCBI
19	Zhou K, Jiang M, Liu Y, Qu Y, Shi G, Yang X, Qin X and Wang X: Effect of bile pigments on the compromised gut barrier function in a rat model of bile duct ligation. PLoS One. 9:e989052014. View Article : Google Scholar : PubMed/NCBI
20	Zhou K, Jiang M, Qin X and Wang X: Role of bilirubin in digestive proteases inactivation in the lower intestine. Dig Liver Dis. 47:438–439. 2015. View Article : Google Scholar : PubMed/NCBI
21	Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR and Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:795–803. 1989. View Article : Google Scholar : PubMed/NCBI
22	Szalai Z, Szász A, Nagy I, Puskás LG, Kupai K, Király A, Berkó AM, Pósa A, Strifler G, Baráth Z, et al: Anti-inflammatory effect of recreational exercise in TNBS-induced colitis in rats: Role of NOS/HO/MPO system. Oxid Med Cell Longev. 2014:9259812014. View Article : Google Scholar : PubMed/NCBI
23	Zhou K, Jiang M, Qin X and Wang X: Role of bilirubin in digestive proteases inactivation in the lower intestine. Dig Liver Dis. 47:438–439. 2015. View Article : Google Scholar : PubMed/NCBI
24	Gilani GS and Sepehr E: Protein digestibility and quality in products containing antinutritional factors are adversely affected by old age in rats. J Nutr. 133:220–225. 2003.PubMed/NCBI
25	Camuesco D, Peran L, Comalada M, Nieto A, Di Stasi LC, Rodriguez-Cabezas ME, Concha A, Zarzuelo A and Galvez J: Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis. 11:265–271. 2005. View Article : Google Scholar : PubMed/NCBI
26	Aube AC, Cherbut C, Barbier M, Xing JH, Roze C and Galmiche JP: Altered myoelectrical activity in noninflamed ileum of rats with colitis induced by trinitrobenzene sulphonic acid. Neurogastroenterol Motil. 11:55–62. 1999. View Article : Google Scholar : PubMed/NCBI
27	Ruyssers NE, de Winter BY, de Man JG, Loukas A, Pearson MS, Weinstock JV, Van den Bossche RM, Martinet W, Pelckmans PA and Moreels TG: Therapeutic potential of helminth soluble proteins in TNBS-induced colitis in mice. Inflamm Bowel Dis. 15:491–500. 2009. View Article : Google Scholar : PubMed/NCBI
28	Kapitulnik J: Bilirubin: An endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol. 66:773–779. 2004. View Article : Google Scholar : PubMed/NCBI
29	Maeda S, Maeda S, Ohno K, Kaji N, Hori M, Fujino Y and Tsujimoto H: Protease-activated receptor-2 induces proinflammatory cytokine and chemokine gene expression in canine keratinocytes. Vet Immunol Immunopathol. 153:17–25. 2013. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Wang L, Tian XY, Liu L, Wong WT, Zhang Y, Han QB, Ho HM, Wang N, Wong SL, et al: Unconjugated bilirubin mediates heme oxygenase-1-induced vascular benefits in diabetic mice. Diabetes. 64:1564–1575. 2015. View Article : Google Scholar : PubMed/NCBI
31	Berberat PO, A-Rahim YI, Yamashita K, Warny MM, Csizmadia E, Robson SC and Bach FH: Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm Bowel Dis. 11:350–359. 2005. View Article : Google Scholar : PubMed/NCBI
32	Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, Itabe H, Kodama T and Maruyama Y: Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 25:155–160. 2005.PubMed/NCBI
33	Lee TS and Chau LY: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 8:240–246. 2002. View Article : Google Scholar : PubMed/NCBI
34	Varga C, Laszlo F, Fritz P, Cavicchi M, Lamarque D, Horvath K, Posa A, Berko A and Whittle BJ: Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. Eur J Pharmacol. 561:164–171. 2007. View Article : Google Scholar : PubMed/NCBI